1
|
Peck-Radosavljevic M. 30 years of the Journal of Hepatology--The flagship journal and the crown-jewel of EASL. J Hepatol 2015; 62:S4-5. [PMID: 25920089 DOI: 10.1016/j.jhep.2015.03.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/17/2015] [Revised: 03/02/2015] [Accepted: 03/02/2015] [Indexed: 12/04/2022]
Affiliation(s)
- Markus Peck-Radosavljevic
- Department of Internal Medicine III, Division of Gastroenterology/Hepatology, Medical University Vienna, 1090 Vienna, Austria.
| |
Collapse
|
2
|
Donaghy ME, Mutrie N. Is exercise beneficial in the treatment and rehabilitation of the problem drinker? A critical review. PHYSICAL THERAPY REVIEWS 2013. [DOI: 10.1179/ptr.1999.4.3.153] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
3
|
Schöniger-Hekele M, Ramskogler K, Hartl D, Lesch OM, Müller C. Exclusion of trisialo-transferrin from carbohydrate-deficient transferrin measurement: advantage in patients with chronic liver disease? Wien Med Wochenschr 2006; 156:216-22. [PMID: 16823539 DOI: 10.1007/s10354-005-0238-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2005] [Accepted: 10/21/2005] [Indexed: 11/29/2022]
Abstract
BACKGROUND Biological markers for chronic alcohol consumption like MCV or gammaGT or carbohydrate deficient transferrin (CDT) are useful, but far from being perfect. In patients with liver disease a reliable marker for chronic alcohol consumption as the underlying etiology is highly needed. Recently, a new ELISA based version of the carbohydrate-deficient-transferrin (CDT-TRISIALO (-)) assay has been developed, which measures asialo-, monosialo- and disialo transferrin, but excludes trisialo- transferrin; that modification suggests higher sensitivity and specificity in detecting recent alcohol consumption in patients. AIMS The study goal was to evaluate the sensitivity, specificity, positive and negative predicitive value of this new carbohydrate-deficient-transferrin assay (CDT-TRISIALO (-)) in a group of patients with liver disease and to compare the results with that of the established CDT assay (CDT-TRISIALO (+)). PATIENTS AND METHODS Our study population consisted of 110 consecutive patients (male: n = 80 [72.7 %], female: n = 30 [27.3 %]) with liver disease of the following etiologies: chronic alcohol consumption (n = 51 [46.4 %]; Out of them 30 alcohol abusing patients were assessed by cage = 1 and 21 alcohol dependent patients were assessed by cage = 2, chronic viral hepatitis (n = 33 [30.0 %]) including 25 [22.7 %] patients with chronic hepatitis C infection and 8 [7.3 %] patients with chronic hepatitis B infection), haemochromatosis (n = 4 [3.6 %]), mechanical cholestasis (n = 17 [15.5 %]) and other liver diseases (n = 5 [4.6 %] including autoimmune hepatitis (n = 2) and primary biliary cirrhosis (n = 3)). 27.3 % of our patients (n = 30) had no liver cirrhosis whereas the majority (72.7 %, n = 80) had liver cirrhosis. RESULTS In our population of liver disease patients the CDT-TRISIALO (-) assay had a sensitivity of 72.7 % and specificity of 58.1 % for recent alcohol consumption at the published cutoff level of 2.6 %. The positive predictive value was 34.0 % and the negative predictive value was 87.8 %. Sensitivity and specificity of the CDT-TRISIALO (+) assay at the recommended cutoff level of 4.7 % were similar, 77.3 % and 49.3 %, respectively. The positive and negative predictive values were 30.9 % and 88.1 %. CDTTRISIALO (+) and CDT-TRISIALO (-) levels increased significantly with higher Child-Pugh stages. CONCLUSION The newly developed carbohydrate deficient transferrin test (CDT-TRISIALO (-)) is of no advantage as compared to the established assay (CDT-TRISIALO (+)) when used in a patient population with liver disease. In that population, normal CDT-TRISIALO (-) helps to exclude recent alcohol consumption; this results from the high negative predictive value of a normal CDT-TRISIALO (-).
Collapse
Affiliation(s)
- Maximilian Schöniger-Hekele
- Klinische Abteilung Gastroenterologie und Hepatologie, Universitätsklinik für Innere Medizin IV, University of Vienna, Austria
| | | | | | | | | |
Collapse
|
4
|
Miller PM, Spies C, Neumann T, Javors MA, Hoyumpa AM, Roache J, Webb A, Kashi M, Sharkey FE, Anton RF, Egan BM, Basile J, Nguyen S, Fleming MF, Dillie KS. Alcohol Biomarker Screening in Medical and Surgical Settings. Alcohol Clin Exp Res 2006; 30:185-93. [PMID: 16441267 DOI: 10.1111/j.1530-0277.2006.00029.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
This article highlights the proceedings of a symposium presented at the 28th Annual Meeting of the Research Society on Alcoholism in Santa Barbara, CA, on June 28, 2005, organized and chaired by Peter Miller. The presentations included (1) Screening for Alcohol Use Disorders in Surgical and Trauma Patients, presented by Claudia Spies; (2) Are Serum Levels of %CDT and GGT Related to Severity of Liver Biopsy Inflammation, Fibrosis, and Steatohepatitis in Patients with Hepatitis C? by Martin Javors; (3) Biochemical Alcohol Screening in the Treatment of Hypertension, presented by Peter Miller; and (4) The Cost-Effectiveness of a New Biomarker, CDT, in a Primary Care Sample, by Michael Fleming. Presentations were discussed by Raymond Anton.
Collapse
Affiliation(s)
- Peter M Miller
- Center for Drug and Alcohol Programs, Charleston, South Carolina 29425, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Fleming MF, Anton RF, Spies CD. A review of genetic, biological, pharmacological, and clinical factors that affect carbohydrate-deficient transferrin levels. Alcohol Clin Exp Res 2004; 28:1347-55. [PMID: 15365305 DOI: 10.1097/01.alc.0000139815.89794.be] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Carbohydrate-deficient transferrin (CDT) is an alcohol biomarker recently approved by the U.S. Food and Drug Administration. This test is increasingly being used to detect and monitor alcohol use in a variety of health care, legal, and industrial settings. The goal of this study is to review the genetic, biological, pharmacological, and clinical factors that may affect CDT levels. METHODS A review of the literature identified 95 research articles that met the authors' criteria and reported potential interactions of a variety of factors on percent and total CDT levels. The review established 12 categories of variables that may affect CDT levels. These categories include (1) alcohol use, (2) genetic factors, (3) race, (4) gender, (5) age, (6) liver disease, (7) iron levels, (8) tobacco use, (9) medication such as estrogen and anticonvulsants, (10) metabolic factors such as body mass index and total body water, (11) chronic medical conditions such as rheumatoid arthritis, and (12) surgical patients. RESULTS There is evidence that %CDT levels are affected by alcohol use, end-stage liver disease, and genetic variants. In addition to these three factors, total CDT levels (CDTect) are also affected by factors that raise transferrin levels such as iron deficiency, chronic illnesses, and menopausal status. Other potential factors such as tobacco and age appear to be confounded by alcohol use. The roles of female gender, low body mass index, chronic inflammatory diseases, and medication on CDT levels require further study. False negatives are associated with female gender, episodic lower level alcohol use, and acute trauma with blood loss. CONCLUSIONS This review suggests that a number of factors are associated with false-positive CDTect and %CDT levels. CDT offers great promise to assist physicians in the care of patients to detect and monitor heavy alcohol use.
Collapse
|
6
|
Golka K, Wiese A. Carbohydrate-deficient transferrin (CDT)--a biomarker for long-term alcohol consumption. JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH. PART B, CRITICAL REVIEWS 2004; 7:319-337. [PMID: 15205047 DOI: 10.1080/10937400490432400] [Citation(s) in RCA: 64] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Carbohydrate-deficient transferrin (CDT) is a biomarker for chronic alcohol intake of more than 60 g ethanol/d. It has been reported to be superior to conventional markers like gamma-glutamyltransferase (GGT) and mean corpuscular volume MCV). This review covers theoretical and analytical aspects, with data from controlled drinking experiments and from different population subgroups such as subjects with different liver diseases or different drinking patterns. CDT determinations are particularly indicated in (1) cases of chronic alcohol consumption and relapses after withdrawal, (2) license reapplication after driving under alcohol influence, (3) differentiating patients with enzyme-inducing medication from those with alcohol abuse, 4) congenital disorders of glycosylation such as carbohydrate-deficient glycoprotein syndrome Ia (CDGS Ia), and (5) patients treated for galactosemia. The main advantage of CDT is its high specificity, as evidenced in combination with increased alcohol consumption. CDT values are not markedly influenced by medication except in immunosuppressed patients, who may show low CDT values. In general, CDT values appear less elevated after alcohol intake in women. The main disadvantage is the relatively low sensitivity. Hence, this parameter is not suitable for screening for subjects with alcohol abuse in the general population. As CDT, GGT, and MCV are connected with chronic alcohol consumption by different pathophysiological mechanisms, a combination of these parameters will further improve the diagnostic value.
Collapse
Affiliation(s)
- Klaus Golka
- Institute for Occupational Physiology at the University of Dortmund, Dortmund, Germany.
| | | |
Collapse
|
7
|
Affiliation(s)
- H Gordon
- The Royal Hampshire County Hospital, Winchester, Hampshire, UK
| |
Collapse
|
8
|
Beisler AT, Kelly RH, Landers JP. Circumventing complement C3 interference in the analysis of carbohydrate-deficient transferrin in fresh serum. Anal Biochem 2000; 285:143-50. [PMID: 10998274 DOI: 10.1006/abio.2000.4717] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
A method for preventing interference by the glycoprotein complement C3 and its beta-globulin split products in the capillary electrophoretic analysis of carbohydrate-deficient transferrin was developed. Inulin was used to activate the alternate complement pathway and convert native C3 into various degradation products whose electrophoretic mobility no longer coincides with the transferrin glycoforms. Capillary electrophoresis and zone electrophoresis on agarose gel were used to monitor reaction conditions for alternate complement pathway activation. Incubation of 50 microL of fresh serum with 180 microL of a 50 mg/mL inulin slurry for 12 h removed the native C3 peak from the beta region. Inulin treatment did not affect electrophoretic behavior of other beta-globulins, including transferrin. Altering the electrophoretic behavior of complement C3, by treating fresh serum with inulin, permits rapid capillary electrophoresis evaluation of carbohydrate-deficient transferrin glycoforms.
Collapse
Affiliation(s)
- A T Beisler
- Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | | | | |
Collapse
|
9
|
Allen J, Sillanaukee P. Carbohydrate-deficient transferrin is a useful marker for the detection of chronic alcohol abuse. Eur J Clin Invest 1999; 29:899-901. [PMID: 10583432 DOI: 10.1046/j.1365-2362.1999.00556.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
10
|
Schmitt UM, Stieber P, Jungst D, Bilzer M, Wachtler M, Heberger S, Seidel D. Carbohydrate deficient transferrin is not a useful marker for the detection of chronic alcohol abuse. Eur J Clin Invest 1999; 29:901. [PMID: 10583433 DOI: 10.1046/j.1365-2362.1999.00557.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
11
|
Yoshikawa K, Umetsu K, Shinzawa H, Yuasa I, Maruyama K, Ohkura T, Yamashita K, Suzuki T. Determination of carbohydrate-deficient transferrin separated by lectin affinity chromatography for detecting chronic alcohol abuse. FEBS Lett 1999; 458:112-6. [PMID: 10481047 DOI: 10.1016/s0014-5793(99)01137-0] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Carbohydrate-deficient transferrin (CDT) has been established as a valuable biological marker for detecting chronic alcohol abuse. To improve the diagnostic efficiency, we studied new CDT determination procedures involving the use of lectin affinity chromatography with Allomyrina dichotoma agglutinin (allo A) and Trichosanthes japonica agglutinin I (TJA-I) to isolate the CDT isoforms CDT-allo A and CDT-TJA, respectively. These procedures, based on detection of the CDT-allo A and CDT-TJA isoforms in sera, showed high sensitivity (100% and 98%, respectively) and high specificity (93% and 85%, respectively). These results demonstrate that the new procedures involving the use of lectin affinity chromatography are more useful for isolating markers in the CDT test than the conventional charge-based separation method.
Collapse
Affiliation(s)
- K Yoshikawa
- Department of Forensic Medicine, Yamagata University School of Medicine, Japan
| | | | | | | | | | | | | | | |
Collapse
|
12
|
BEAN PAMELA. Carbohydrate-deficient transferrin in the assessment of harmful alcohol consumption: diagnostic performance and clinical significance. Addict Biol 1999; 4:151-61. [PMID: 20575781 DOI: 10.1080/13556219971650] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
The last decade saw the emergence of carbohydrate-deficient transferrin (CDT) as the most promising marker for the diagnosis of alcohol abuse. Daily alcohol consumption of four beers, four glasses of wine or three standard drinks causes increased concentrations of CDT in serum. CDT is serum transferrin with a reduced content of oligosaccharides due to the detrimental effects of alcohol metabolism on the glycosylation pathway of hepatocytes and/or the increased activity of circulating glycosidases in serum. Most current CDT procedures entail separation of normal transferrin from CDT in a charged matrix-like isoelectric focusing and ion exchange chromatography, followed by detection/quantitation of CDT by a myriad of immunoassays: immunoblotting, radioimmunoassay, enzyme immunoassay and nephelometry. New CDT procedures present the advantages of improved performance, inexpensive automation and CDT results expressed as a percentage of total serum transferrin. CDT's major asset is its high specificity in well-defined populations i.e. individuals ingesting 60 g alcohol daily for at least a week.The sensitivity rates, which vary between 22% and 81%, depend on the amount of alcohol ingested, time of sample collection after the cessation of drinking, age, gender and the cut-off point chosen for analysis of tests' results. Regarding clinical applications, best outcome is achieved when the test is used to confirm a suspicion of alcohol abuse and when monitoring abstinence and relapses.The low prevalence of alcohol abuse in the general population challenges its use as a screening test.With the advent of inexpensive automation and the constant emergence of innovative, improved tests, we are seeing the rise of a new era in alcohol abuse diagnosis as affordability and education allows widespread use of CDT in a variety of settings.
Collapse
|
13
|
Malcolm R, Anton RF, Conrad SE, Sutherland S. Carbohydrate-deficient transferrin and alcohol use in medical examiner cases. Alcohol 1999; 17:7-11. [PMID: 9895031 DOI: 10.1016/s0741-8329(98)00026-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Carbohydrate-deficient transferrin (CDT) has been studied as an index of heavy alcohol use. The present study evaluates the utility of CDT as a marker for chronic alcohol use in medical examiner cases. Over a 5-month period, serum specimens were collected in consecutive deaths that were referred to the medical examiner's office (N = 25). Manner of death was accidental in nine cases, homicide/suicide for eight cases, and natural causes for seven cases. Fifteen of the 17 cases having alcohol abuse had positive CDT levels above threshold, indicating chronic use (sensitivity 88%). Eight cases had no evidence of alcohol abuse but three of these cases had CDT levels also above threshold (specificity 63%). There was no correlation between serum CDT levels and the time of death to blood collection for the total sample, indicating that CDT is stable postmortem for at least 36 h. CDT appears to have value as a marker of ante-mortem alcohol use prior to time of death in medical examiner cases.
Collapse
Affiliation(s)
- R Malcolm
- Department of Psychiatry, Medical University of South Carolina, Charleston 29425-0742, USA
| | | | | | | |
Collapse
|
14
|
Helander A, Vabö E, Levin K, Borg S. Intra- and interindividual variability of carbohydrate-deficient transferrin, γ-glutamyltransferase, and mean corpuscular volume in teetotalers. Clin Chem 1998. [DOI: 10.1093/clinchem/44.10.2120] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
Blood samples for determination of the biochemical alcohol markers carbohydrate-deficient transferrin (CDT) in serum, γ-glutamyltransferase (GGT) in serum, and erythrocyte mean corpuscular volume (MCV) were collected once every 1–2 weeks over ∼5 months from 10 female and 4 male teetotalers. Mean values for serum CDT (using the CDTectTM assay) ranged from 9.9 to 29.4 units/L (median, 14.2 units/L), and the highest results were obtained in the women. The mean values for serum GGT ranged from 0.15 to 0.49 μkat/L (median, 0.30 μkat/L, or 18 U/L) except for one woman with a very high mean of 3.07 μkat/L. For MCV, the mean values ranged from 79.5 to 91.5 fL. Two women showed several CDT results above the upper reference limit (mean values, 27.6 and 29.4 units/L, respectively); however, their GGT and MCV values fell within the reference intervals. One of these women exhibited an increased total transferrin concentration (mean value, 5.38 g/L), which was possibly related to the use of oral contraceptives and/or a low serum iron concentration. When the CDTect value was expressed relative to total transferrin, a ratio within the reference interval was observed for this woman but not for the other woman with increased CDTect values. The present study demonstrates a considerable variation between individuals in CDT, GGT, and MCV without drinking any alcohol. The results also show that these baseline values are fairly constant over time within the same individual.
Collapse
Affiliation(s)
- Anders Helander
- Department of Clinical Neuroscience, Karolinska Institute, Center for Dependency Disorders at St. Görans & Karolinska Hospital, S-10229 Stockholm, Sweden
| | - Erling Vabö
- Department of Clinical Neuroscience, Karolinska Institute, Center for Dependency Disorders at St. Görans & Karolinska Hospital, S-10229 Stockholm, Sweden
| | - Klas Levin
- Nova Medical Calab, St. Görans Hospital, S-11281 Stockholm, Sweden
| | - Stefan Borg
- Department of Clinical Neuroscience, Karolinska Institute, Center for Dependency Disorders at St. Görans & Karolinska Hospital, S-10229 Stockholm, Sweden
| |
Collapse
|
15
|
Schmitt UM, Stieber P, Jüngst D, Bilzer M, Wächtler M, Heberger S, Seidel D. Carbohydrate-deficient transferrin is not a useful marker for the detection of chronic alcohol abuse. Eur J Clin Invest 1998; 28:615-21. [PMID: 9767355 DOI: 10.1046/j.1365-2362.1998.00343.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND The role of carbohydrate-deficient transferrin (CDT) as a reliable marker for the detection of chronic alcohol abuse has been discussed controversially. METHODS Therefore, we investigated CDT in the sera from 405 subjects with different alcohol intake. Besides healthy control subjects (n = 42), inpatients and outpatients in a department of gastroenterology (n = 325) and patients admitted to a department of otorhinolaryngology (n = 38) were studied. A total of 213 patients suffered from various forms of liver diseases, and 89 patients had liver transplantation. CDT values were determined by a double-antibody radioimmunoassay. RESULTS In the 241 alcohol-abstinent subjects, CDT levels ranged from 3 to 90 units L-1 (median = 12); the 92 moderate drinkers (20-60 g of alcohol per day) showed values from 3 to 40 units L-1 (median = 12), and the 72 subjects with chronic alcohol abuse (> 60 g per day) revealed CDT levels from 3 to 100 units L-1 (median = 16). The diagnostic specificity for alcohol abuse was 86.8% for men (sensitivity 36.9%) and 95% for women (sensitivity 0%). CONCLUSION Our data indicate that measurement of CDT does not reach clinical use in the detection of chronic alcohol abuse in an unselected population because of its insufficient specificity and sensitivity.
Collapse
Affiliation(s)
- U M Schmitt
- Klinikum Grosshadern, Ludwig-Maximilians-University Munich, Germany.
| | | | | | | | | | | | | |
Collapse
|
16
|
KEATING JAMES, CHEUNG CONNIE, PETERS TIMOTHYJ, PRZEMIOSLO ROBERT, WILLIAMS ROGER, SHERWOOD ROYA. Carbohydrate deficient transferrin in alcoholic and non-alcoholic liver disease: a comparison of two assay methods. Addict Biol 1998; 3:205-11. [PMID: 26734825 DOI: 10.1080/13556219872263] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
Carbohydrate-deficient transferrin (CDT) was assayed in 105 patients with non-alcohol-related liver diseases, 50 patients with alcohol-induced liver disease and 40 alcohol misusers with minimal hepatic dysfunction. The patients with liver disease were hospitalized for assessment of suitability for orthotopic liver transplantation. CDT was measured by two commercially available micro anion exchange methods; CDTect (Pharmacia) and %CDT (AXIS). Additionally, total transferrin was measured to allow expression of the CDTect results as 'relative' measurements. Overall, 41/105 (39%) of patients with non-alcohol-related liver diseases had a raised CDTect result, 13/105 (12%) had a raised %CDT result and 26/105 (25%) an abnormal CDTect/total transferrin ratio. In general, patients with cholestatic liver disease, primary biliary cirrhosis or primary sclerosing cholangitis had more 'false positive' results by CDTect than did those with viral or autoimmune hepatitis. The sensitivity of the two methods for the detection of alcohol misuse was similar; CDTect 77%, %CDT 65% and CDTect/total transferrin ratio 70%. This was, however, lower than the sensitivity of the conventional marker GGT (82%). In patients with severe liver disease, where up to 30% of the serum total transferrin concentrations fall outside the reference range, 'relative' CDT methods have greater specificity than 'absolute' measurements.
Collapse
|
17
|
Perret R, Froehlich F, Lavanchy D, Henry H, Bachman C, Pecoud A, Bianchi L, Gonvers JJ. Is Carbohydrate-Deficient Transferrin a Specific Marker for Alcohol Abuse? A Study in Patients with Chronic Viral Hepatitis. Alcohol Clin Exp Res 1997. [DOI: 10.1111/j.1530-0277.1997.tb04457.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
18
|
Abstract
AbstractThis review includes a description of short-term and long-term markers of ethanol intake and their clinical utility. The major portion of this report is a summary of studies on fatty acid ethyl ester, a new marker for monitoring both acute and chronic ethanol intake. With the markers described in the review, algorithms to assess recent ethanol intake, chronic ethanol intake, and end organ damage are included to provide a practical approach to the evaluation of the patient.
Collapse
|
19
|
Rublo M, Caballería J, Deulofeu R, Caballería L, Gassó M, Parés A, Vilella A, Giménez A, Ballesta A, Rodés J. Carbohydrate-deficient transferrin as a marker of alcohol consumption in male patients with liver disease. Alcohol Clin Exp Res 1997; 21:923-7. [PMID: 9267545 DOI: 10.1111/j.1530-0277.1997.tb03859.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Carbohydrate-deficient transferrin (CDT) has been proposed as a marker of alcohol abuse. However, its value in patients with associated liver disease is still controversial. The aim of the study was to investigate the usefulness of CDT as a marker of alcohol consumption in patients with liver disease. We measured serum levels of CDT and those of commonly used hematological and biochemical markers, mean corpuscular volume (MCV), transaminases (AST and ALT), and gamma-glutamyltransferase in 179 male subjects divided into four groups: 45 active drinkers (13 with normal liver, 21 with fibrosteatosis, and 11 with liver cirrhosis), 45 abstinent chronic alcoholics (18 with and 27 without liver disease), 58 patients with nonalcoholic liver disease, and 31 healthy controls. Serum CDT in active alcoholics was 37.5 +/- 3.6 units/liter, being significantly higher than that of abstinent alcoholics (20.3 +/- 1.5 units/liter), patients with nonalcoholic liver disease (18.1 +/- 1.1 units/liter), and controls (13.1 +/- 0.8 units/liter). Contrary to the other markers, no significant differences were observed in CDT values in relation with the presence and severity of liver disease in either the active drinkers or in the abstinent alcoholics. The sensitivity and specificity of CDT as a marker of alcoholism in the series as a whole was 64% and 82%, respectively, similar to the best conventional marker, MCV (64 and 82%). In patients with liver disease, CDT maintained good sensitivity (72%) and specificity (83%). Receiver operating characteristic analysis confirmed that CDT had a similar diagnostic value to that of MCV, but better than gamma-glutamyl-transferase and transaminases for the detection of alcohol abusers. The good diagnostic efficacy of CDT remained unchanged when analyzing only patients with liver disease. We conclude that serum CDT is a good marker of alcoholism and is less influenced than the currently used biochemical markers for associated liver disease. Thus, CDT is an effective laboratory test to detect alcohol abuse regardless of the presence of alcoholic liver disease.
Collapse
Affiliation(s)
- M Rublo
- Liver Unit, Hospital Clínic i Provincial, University of Barcelona, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Murawaki Y, Sugisaki H, Yuasa I, Kawasaki H. Serum carbohydrate-deficient transferrin in patients with nonalcoholic liver disease and with hepatocellular carcinoma. Clin Chim Acta 1997; 259:97-108. [PMID: 9086297 DOI: 10.1016/s0009-8981(96)06473-x] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Serum carbohydrate-deficient transferrin (CDT) is used as a reliable and specific marker of alcohol consumption. However, recent studies have shown false-positive CDT test results in nonalcoholic liver disease. We examined the clinical significance of serum CDT in nonalcoholic liver disease, especially hepatocellular carcinoma. Serum CDT was measured in 23 teetotallers, 56 patients with alcoholic liver disease, 84 patients with viral liver disease and 67 patients with hepatocellular carcinoma, with an Axis %CDT radioimmunoassay kit, and the results were expressed as percentages of the total transferrin (%CDT). The mean serum %CDT value was increased 1.8-fold in alcoholic liver fibrosis and 3.8-fold in alcoholic liver cirrhosis compared with the teetotallers. The serum %CDT values in viral chronic hepatitis were similar to those of the teetotallers, and were increased 2.0-fold in viral liver cirrhosis. False-positive results were found in 10 (37%) of the 27 patients with viral liver cirrhosis. The mean serum %CDT value was increased 2.5-fold in hepatocellular carcinoma, and false-positive results were found in 31 (46%) of the 67 patients. The serum %CDT value was related to the severity of Child grade, the size of tumor and the grade of histological differentiation. These results suggest that the ability of serum CDT test to detect chronic alcoholism may be reduced in patients with nonalcoholic liver cirrhosis and those with hepatocellular carcinoma.
Collapse
Affiliation(s)
- Y Murawaki
- Second Department of Internal Medicine, Tottori University School of Medicine, Yonago, Japan
| | | | | | | |
Collapse
|
21
|
Henriksen JH, Grønbaek M, Møller S, Bendtsen F, Becker U. Carbohydrate deficient transferrin (CDT) in alcoholic cirrhosis: a kinetic study. J Hepatol 1997; 26:287-92. [PMID: 9059948 DOI: 10.1016/s0168-8278(97)80043-8] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
BACKGROUND/AIMS Carbohydrate deficient transferrin has been introduced as a marker of excessive alcohol intake. The present study was undertaken in order to measure the circulating level of carbohydrate deficient transferrin in patients with alcoholic cirrhosis and to assess arteriovenous kinetics of carbohydrate deficient transferrin in liver and kidney. METHODS/RESULTS The median value of serum carbohydrate deficient transferrin was 16.0 U/l in patients with alcoholic cirrhosis (n = 41), and this value was not significantly different from that of a normal control group (median 17.4 U/l, n = 55, ns). Carbohydrate deficient transferrin was significantly higher in patients with cirrhosis and high current alcohol intake than in abstaining patients (20 vs. 14 U/l, p < 0.05). Similarly, controls with a high current alcohol intake (> 50 g/day) had a significantly higher carbohydrate deficient transferrin concentration than controls with a low alcohol intake (< 10 g/day) (36 vs. 14.9 U/l, p < 0.005). No significant differences were detected between carbohydrate deficient transferrin in artery and liver vein or artery and renal vein, either in patients with alcoholic cirrhosis (n = 11) or in controls (n = 8), which indicates a slow turnover rate of carbohydrate deficient transferrin. Food ingestion did not affect the circulating level of carbohydrate deficient transferrin, and the analysis of carbohydrate deficient transferrin was almost unaffected by the presence of ethanol in plasma within the biological range (ethanol 0-100 mmol/l). CONCLUSIONS Our results suggest that measurement of carbohydrate deficient transferrin may be used in patients with alcoholic cirrhosis. High current alcohol intake is associated with higher carbohydrate deficient transferrin levels than in those with low alcohol intake, but the overlap is substantial in patients with cirrhosis. Carbohydrate deficient transferrin has a low turnover rate in both patients with cirrhosis and normals.
Collapse
Affiliation(s)
- J H Henriksen
- Department of Clinical Physiology, Hvidovre Hospital, University of Copenhagen, Denmark
| | | | | | | | | |
Collapse
|